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Abstract
Background: Malignant gliomas are associated with a high mortality rate, and effective treatment options are
limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative.
Methods: In this study, we investigated the in vitro effects of the novel reversible chromosomal region
maintenance 1 (CRM1) inhibitor S109 on cell proliferation in human gliomas. S109 was also evaluated in an
intracranial glioblastoma xenograft model.
Results: We found that high expression of CRM1 in glioma is a predictor of short overall survival and poor patient
outcome. Our data demonstrate that S109 significantly inhibits the proliferation of human glioma cells by inducing
cell cycle arrest at the G1 phase. Notably, we observed that high-grade glioma cells are more sensitive to S109
treatment compared with low-grade glioma cells. In an intracranial mouse model, S109 significantly prolonged the
survival of tumor-bearing animals without causing any obvious toxicity. Mechanistically, S109 treatment
simultaneously perturbed the three core pathways (the RTK/AKT/Foxos signaling pathway and the p53 and Rb1
tumor-suppressor pathways) implicated in human glioma cells by promoting the nuclear retention of multiple
tumor-suppressor proteins.
Conclusions: Taken together, our study highlights the potential role of CRM1 as an attractive molecular target for
the treatment of human glioma and indicates that CRM1 inhibition by S109 might represent a novel treatment
approach.
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Background
Gliomas account for approximately 70 % of all primary
malignant brain tumors [1]. On the basis of histological
features, gliomas are classified into four distinct subtypes
by the World Health Organization [2]: grade I (pilocytic
astrocytoma), grade II (diffuse astrocytoma), grade III
(anaplastic astrocytoma), and grade IV (glioblastoma).
Glioblastomas account for approximately 60 to 70 % of
malignant gliomas. Despite advances in the understand-
ing of glioma biology and the development of new treat-
ment options, the median survival for patients with
glioblastomas is merely 12 to 15 months [3]. Thus, there
is an urgent need for the development of novel targeted
therapeutics.
Two decades of molecular studies together with recent
large-scale cancer gene sequencing efforts have identi-
fied three critical signaling pathways that are misregu-
lated in human glioblastomas: the RTK/PI3K/AKT/
Foxos signaling pathway and the p53 and Rb1 tumor
suppressor-pathways [4–6]. Consistent with these
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findings, the simultaneous deletion of Pten-, p53-, and
Nf1-mediated CRISPR/Cas9 can promote the develop-
ment of highly aggressive tumors resembling human
glioblastomas in the mouse brain [7]. Furthermore,
nearly all subtypes of gliomas are associated with the
amplification and overexpression of the epidermal
growth factor receptor (EGFR) gene [8]. However, inhib-
itors of receptor tyrosine kinases (RTK) [9–11], PI3K
[12], and mTOR [13, 14] have exhibited only modest ac-
tivity in glioma, with response rates of 0 to 15 % and no
prolongation of 6-month progression-free survival [15,
16]. Given the complexity and redundancy of the signal-
ing networks associated with glioma, the simultaneous
targeting of critical oncogenic pathways might constitute
a promising treatment approach.
Chromosomal region maintenance 1 (CRM1), also re-
ferred to as exportin 1 (XPO1) [17], is a promising
therapeutic target for gliomas. Increased CRM1 expres-
sion has been observed in gliomas and is correlated with
a poor prognosis and higher grade of malignancy [18].
CRM1 is a key member of the karyopherin β superfamily
of nuclear transport receptors, which mediate the trans-
port of specific proteins from the nucleus to the cyto-
plasm in eukaryotic cells [19]. CRM1 is the key exporter
of multiple tumor-suppressor proteins [20], including
Foxos, Rb1, p53, p21, p27, and survivin. Accumulating
lines of evidence suggest that the misregulation of nu-
clear protein export dynamics is involved in cancer cell
survival, tumor progression, and drug resistance [21, 22].
These observations have stimulated considerable interest
in drugs targeting the nuclear export of proteins.
Leptomycin B (LMB), the first natural inhibitor of
CRM1 to be identified, can covalently bind the Cys528
residue in the cargo-binding region of CRM1 [23]. How-
ever, the phase I clinical trial of LMB was terminated
due to its toxic effects and lack of efficacy at tolerable
doses [24]. Recently, a novel class of selective inhibitors
of nuclear export (SINE) has been developed [25–27].
One member of this class, selinexor (KPT-330), is
currently undergoing phase I/II clinical trials to evalu-
ate its effect in several solid and hematologic malig-
nancies [28]. KPT-330 is a CRM1 inhibitor that forms
a slowly reversible covalent bond with CRM1, and
preliminary evidence indicates that it exhibits a rela-
tively favorable drug tolerability profile. These find-
ings suggest that a selective and reversible inhibitor
might offer an improved tolerability profile. However,
most of the currently available CRM1 inhibitors func-
tion by irreversibly binding to Cys528. Recently, we
developed the novel reversible CRM1 inhibitor S109,
which can induce CRM1 protein degradation [29].
In the present study, we evaluated the mechanism and
therapeutic potential of a reversible CRM1 inhibitor,
S109, in the treatment of human glioma. Specifically, we
investigated the therapeutic efficacy of S109 in vitro and
in intracranial mouse models of malignant glioma and
elucidated the mechanism underlying S109-mediated
anti-glioma activity. This study provides a basis for fur-
ther clinical investigations of S109.
Methods
Glioma and non-tumor human brain tissues
Human glioma specimens (obtained through surgical re-
section) and non-tumorous brain tissues (obtained from
patients with internal decompression in cerebral trauma)
were obtained from the Affiliated Hospital of Xuzhou
Medical College (Xuzhou, China). Written informed
consent was obtained from all of the participants, and
this study was approved by the Ethics Committee of the
Affiliated Hospital of Xuzhou Medical University.
Cell lines and culture conditions
The human glioma cell lines U251 and SHG-44 and
glioblastoma cell lines U118 and U87 were purchased
from the Shanghai Cell Bank, Chinese Academy of Sci-
ences. All of the cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Carlsbad,
CA, USA) supplemented with 10 % fetal bovine serum
(FBS, Gibco) in a humidified incubator with 5 % CO2 at
37 °C.
Antibodies and reagents
Primary antibodies against CRM1, GAPDH, actin,
RanBP1, and p53 were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA, USA), and antibodies
against cyclin D1, Cdc25B, p27, p21, Foxo1, p-Foxo1,
Akt, p-Akt, p-Rb1, and histone H3 were purchased from
Cell Signaling Technology (CST, Beverly, MA, USA).
Cytotoxicity assay
The cell counting kit-8 (CCK-8) assay was used to assess
cell viability following S109 treatment. Briefly, glioma
cells were plated in triplicate in 96-well plates (2 × 103
cells per well). After overnight incubation, the cells were
treated with various concentrations of S109 for 72 h.
The cells were subsequently washed three times with
phosphate-buffered saline (PBS), and 10 μL of CCK8
was added to each well. Following a 3-h incubation, the
absorbance was measured using a microplate reader at a
wavelength of 450 nm.
EdU incorporation assays
Cell proliferation was assessed using the Cell-Light™
EdU Cell Proliferation Detection Kit (RiboBio, China)
according to the manufacturer’s instructions. The cells
were treated with various concentrations of S109 for
12 h. Subsequently, the cells were incubated with 50 μM
EdU for 2 h and then fixed in 4 % paraformaldehyde for
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30 min. After permeabilization with 0.5 % Triton X-100,
the cells were incubated with Apollo® reaction cocktail
for 30 min in the dark. The cellular DNA was stained
with DAPI for 15 min. Following three washes with PBS,
the cells were examined and imaged using an inverted
microscope (Olympus, Japan).
Colony formation assay
The cells were seeded at a density of 500 cells/well in 6-
well culture plates. The plated cells were treated with
different concentrations of S109 for 12 h, and fresh
medium was subsequently added. After a 14-day incuba-
tion, the cells were fixed in methanol for 15 min and
stained with 0.1 % crystal violet solution. Positive colony
formation, defined as colonies with more than 50 cells,
was confirmed by manual counting.
Co-immunoprecipitation
Immunoprecipitation assays were performed as previ-
ously described [30]. Briefly, cells treated with 0.1 %
DMSO or S109 were lysed in cold lysis buffer. The
supernatant was incubated with anti-CRM1 antibody for
8 h and then with protein G-Sepharose 4B (Roche, Basel,
Switzerland) overnight at 4 °C while rocking. The immu-
noprecipitated complexes were washed three times with
lysis buffer and analyzed by western blot.
Immunofluorescence microscopy
The cells were then treated with S109 and subse-
quently fixed for 20 min with 4 % paraformaldehyde
in PBS. The cell membranes were subsequently
permeabilized in 0.1 % Triton X-100 and blocked
with 1 % bovine serum albumin (BSA) in PBS. The
cells were then incubated with the indicated antibody.
DAPI was used for nuclei labeling (blue), and the
stained cells were visualized and imaged through
fluorescence microscopy (Olympus, Japan).
Establishment of CRM1-WT and CRM1-C528S stable cell
lines
The cDNA encoding human CRM1-WT or CRM1 with
the C528S mutation was inserted into the pWPXLd-
puro lentiviral vector containing a sequence encoding a
flag tag. The viruses were produced in 293FT cells by
co-transfecting the recombinant plasmids with the
helper plasmids pSPXA2 and pMD2.G. The U87 cells
were then transfected with the CRM1-WT or CRM1-
C528S lentivirus for 48 h and then continuously cultured
in medium containing 2.5 μg/mL puromycin. The sur-
viving cells were cultured and used to generate cell lines
that stably expressed CRM1-WT or CRM1-C528S.
CRM1 expression and survival analysis in patients with
glioma
CRM1 gene expression datasets were obtained from R2:
microarray analysis and visualization platform (http://
hgserver1.amc.nl/cgi-bin/r2/main.cgi). The prognosis
analysis was conducted online, and cutoff values for sep-
arating high and low expression groups were determine
by auto scan.
In vivo studies
All animal experimental protocols were approved by the
Ethics Committee of the Xuzhou Medical University.
Male athymic BALB/c nude mice aged 5 to 6 weeks
were obtained from the Experimental Animal Center of
Xuzhou Medical College. Firefly luciferase-labeled U87
cells (5 × 105 cells per mouse) were intracranially
injected into the right striatum of nude mice using a
small animal stereotactic apparatus as described in our
previous report [31, 32]. Once the presence of a tumor
was confirmed by imaging system, the tumor-bearing
mice were randomly divided into one of the following
three treatment groups (n = 8 per group): S109 at
20 mg/kg, S109 at 50 mg/kg, and vehicle. The drugs and
vehicle were delivered daily via intraperitoneal injections.
Tumor growth was monitored at regular intervals by
injecting D-luciferin 10 min prior to imaging using a
NightOWL LB 983 small-animal in vivo imaging system
(Berthold Technologies, Germany).
Histopathology and immunofluorescence staining
The whole brain and vital organs (lung, liver, testis, kid-
ney, and heart) of the control and treated mice were har-
vested on day 21, fixed in 4 % paraformaldehyde and
dehydrated sequentially in 20 and 30 % sucrose at 4 °C
until they sank. The frozen glioma tissues were serially
sectioned at a thickness of 12 μm, and the slide with the
largest tumor area was stained with hematoxylin and
eosin (H&E).
Statistical analysis
The statistical analyses were performed using the Graph-
Pad Prism 5 software package. All of the data are pre-
sented as the means ± SEM of three independent
experiments. Comparisons of the mean values between
the control and treated groups were performed using
Student’s t test. A Kaplan-Meier survival curve and the
log-rank test were used for the in vivo survival analysis.
P values <0.05 were considered statistically significant.
Results
High CRM1 expression predicts poor survival in patients
with glioma
To evaluate the possibility that CRM1 is important for
glioma, we analyzed the R2 genomics database, for
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which microarray-based gene expression and clinical
outcome data were available. The prognosis analysis was
conducted online, and cutoff values for separating high
and low expression groups were determine by auto scan.
As shown in Fig. 1a, CRM1 gene was highly expressed in
131 out of 273 cases of glioma. The distinction between
high and low CRM1 was of prognostic significance, as
the overall survival rate was markedly reduced in cases
exhibiting high CRM1 expression. Next, we assessed
CRM1 protein expression in human glioma tissues
through a western blot analysis and found that CRM1
was highly expressed in all tumor samples compared
with non-tumorous brain tissues (Fig. 1c). We analyzed
the R2 genomics database, for which microarray-based
gene expression and clinical outcome data were avail-
able. These data indicate that CRM1 expression is sig-
nificantly higher in grade III and IV gliomas than in
grade II tumors (Additional file 1: Figure S1A). These
findings indicated that up-regulation of CRM1 in a sub-
set of glioma leads to inferior outcome.
S109 inhibits the proliferation and colony-formation abil-
ity of glioma cells
To examine the effect of S109 on glioma cell prolifera-
tion, we evaluated the viability of glioma cells treated
with S109 using the CCK-8 and EdU assays. We found
that S109 markedly inhibited cell proliferation in a dose-
dependent manner in the five cell lines evaluated
(Fig. 1b). Interestingly, the IC50 observed for the high-
grade glioma cell lines U87 and U118 was twofold lower
than that observed for the low-grade glioma cells lines
U251 and SHG44. Furthermore, knockdown of CRM1
significantly decreased the growth of U87 cells (Add-
itional file 1: Figure S1B and S1C). The EdU assay dem-
onstrated that S109 significantly reduced the number of
EdU-positive cells in a dose- (Fig. 1d) and time-
dependent manner (Additional file 1: Figure S2). The ex-
posure of U87 cells to 0.5 and 1 μM S109 reduced the
proliferation of these cells by 54.2 and 29.3 %, respect-
ively (Fig. 1e).
To evaluate the long-term effects of S109 on cell pro-
liferation, a clonogenic assay was performed. As shown
in Fig. 1f–i, S109 treatment induced a dose-dependent
inhibition of the clonogenic potential of U87 and U251
cells. Compared with the control group, the colony for-
mation in U87 cells was markedly decreased by 50.7,
34.1, and 22.2 % in response treatment with 0.5, 1, and
2 μM S109, respectively. Taken together, these results
demonstrate that S109 can effectively inhibit the prolif-
eration of glioma cells. More importantly, high-grade gli-
oma cells are more sensitive to S109 treatment than
low-grade glioma cells.
S109 induces G1 arrest and modulates the expression of
cell cycle regulators
To determine whether the S109-induced decrease in cell
proliferation resulted from the abrogation of cell cycle
progression, propidium iodide flow cytometry assays
were performed. In the U87 cell population treated with
the DMSO vehicle, 53.3 % of the cells were in the G1
phase, whereas the cell populations treated with 1 and
2 μM S109 exhibited higher percentages of cells (70.5
and 79.7 %, respectively) in the G1 phase (Fig. 2a, b).
Similar effects on cell cycle progression were obtained in
U251 cells treated with S109 (Fig. 2c, d). However, no
significant changes in cell apoptosis were observed in ei-
ther U87 or U251 cells treated with S109 (data not
shown). These data clearly demonstrated that S109 se-
lectively induces G1 cell-cycle arrest but does not affect
apoptosis in glioma cells.
We next explored the effect of S109 on cell cycle regu-
lation signaling through western blot analysis. As shown
in Fig. 2e, f, S109 treatment significantly up-regulated
the expression levels of the cell cycle inhibitory proteins
p21 and p27 in a dose- and time-dependent manner. In
addition, cyclin D1 and Cdc25B expression was mark-
edly decreased in S109-treated cells compared with con-
trol cells. These results confirm that S109 induces G1
arrest by modulating multiple cell cycle regulatory
proteins.
S109 reversibly regulates the expression and function of
CRM1 in human glioma cells
The effect of S109 on the level of CRM1 protein in gli-
oma cells was investigated through western blot analysis.
As shown in Fig. 3a, treatment with increasing concen-
trations of S109 significantly decreased the expression
level of CRM1 protein in both U87 and U251 cells.
However, the classic irreversible CRM1 inhibitor LMB
did not induce degradation of CRM1 protein (Fig. 3b).
Furthermore, pretreatment of U87 cells with LMB com-
pletely blocked S109-induced CRM1 protein
(See figure on previous page.)
Fig. 1 S109 inhibits the proliferation and colony formation ability of glioma cells. a Kaplan-Meier analysis of overall survival for the French data.
CRM1 had high expression in 131 out of 273 cases of glioma was associated with poor patient survival. b Structure of S109 and assessment of cell
viability. Cells were treated with vehicle or various concentrations of S109 for 72 h. The cell viability was measured using CCK-8 assays. c Total
protein extracts isolated from non-tumorous brain tissues and glioma tissues were evaluated through western blotting assays. d Representative
images from the EdU analysis of cell proliferation after treatment of U87 cells with S109. f, h S109 suppresses colony formation of U87 and U251
cells in a dose-dependent manner. e, g, i Quantitative results of the EdU incorporation and clonogenic assays of U87 and U251 cells
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degradation, suggesting that LMB and S109 compete for
CRM1 binding (Fig. 3d). We then investigated the
changes in the CRM1 protein level over time after cell
transfer from S109-containing media to compound-free
media. Six hours after the media exchange, the quantity
of CRM1 protein in cells that had been treated with
S109 was comparable to that of the control cells (Fig 3c).
To determine whether S109-induced CRM1 degradation
is associated with the ubiquitin-proteasome system, we
treated U87 cells with S109 alone or in combination
with the proteasome inhibitor MG132. S109 induced a
rapid degradation of CRM1 protein in the absence of
MG132, and this degradation was completely blocked by
MG132-induced proteasome inhibition (Fig. 3e). These
data suggest that S109 induces CRM1 protein degrad-
ation via the ubiquitin-proteasome system.
To investigate whether S109 is capable of functionally
inactivating CRM1 in glioma cells, we analyzed the
Fig. 2 S109 induces cell-cycle arrest and regulates the expression of cell cycle-related proteins in glioma cells. a, c U87 and U251 cells were
treated with S109 for 12 h. The cells were stained with PI and evaluated using a flow cytometer. b, d Quantitative analysis of the cell-cycle-phase
distribution of the cells in the control group and the S109-treated group. e, f U87 cells were treated with 0.1 % DMSO or S109 for 12 h or treated
with 2 μM S109 for different durations (0–12 h). The cells were then harvested and examined through western blot analysis with the
indicated antibodies
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subcellular localization of NES-GFP and RanBP1, which
are canonical markers of CRM1 inhibition. CRM1 ex-
ports cargo proteins via the recognition of a specific
leucine-rich nuclear export signal (NES) consensus se-
quence in its substrates. In the control cells, NES-GFP
was actively exported and localized predominantly to the
cytoplasm (Fig. 3f, g). Notably, the exposure of U87 and
U251 cells to S109 resulted in the progressive nuclear
accumulation of NES-GFP. We then analyzed the sub-
cellular localization of RanBP1, a protein known to be
exported to the cytoplasm in a CRM1-dependent man-
ner. As presented in Fig. 3h, i, RanBP1 localized exclu-
sively to the cytoplasm in untreated glioma cells, but
RanBP1 nuclear accumulation was observed as early as
2 h post-exposure to S109 in both U87 and U251 cells.
To examine whether S109 reversibly binds to CRM1
in glioma cells, we analyzed the subcellular localization
of RanBP1 after cell transfer from S109-containing
medium to S109-free medium. After 2 h of treatment,
the S109-containing medium was removed, and the cells
Fig. 3 S109 decreases CRM1 protein expression and inhibits CRM1-dependent nuclear export in glioma cells. a U87 and U251 cells were incu-
bated with S109 for 12 h, and the CRM1 protein levels were analyzed by immunoblotting. b U87 cells were treated with LMB for 12 h and then
evaluated by western blot analyses. c U87 cells were treated with S109 (2 μM) for 12 h. The drugs were then washed out, and fresh medium was
added. The cells were further incubated for the indicated times, and whole-cell lysates were analyzed by immunoblotting. d U87 cells were
treated with S109 in the presence or absence of LMB (2 nM) for 12 h. The CRM1 protein levels were examined by western blot analysis. e U87
cells were treated with LMB (2 nM) and S109 (1 μM) in the presence or absence of MG132 (10 μM) for 12 h. Total proteins were extracted and
used for immunoblotting analysis. f, g U87 and U251 cells were transiently transfected with the NES-GFP plasmid and treated with LMB and S109
at the indicated concentrations for 2 h. Fixed cells were stained with DAPI and analyzed by fluorescence microscopy. h, i U87 and U251 cells were
incubated in the presence or absence of S109 for 2 h. The cells were then fixed, stained with RanBP1 antibody and DAPI, and analyzed by
fluorescence microscopy
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were washed twice and incubated with fresh medium for
another 2 h. Interestingly, in the cells treated with S109,
RanBP1 almost completely relocated to the cytoplasm
after removal of the compound. However, in the cells in-
cubated with LMB, RanBP1 was retained in the nucleus
following transfer to medium without S109 (Additional
file 1: Figure S3). Taken together, these results indicate
that S109 can reversibly inhibit the function of CRM1 in
glioma cells.
S109 perturbs the core pathways associated with glioma
by targeting CRM1-associated tumor-suppressor proteins
To gain further insight into the mechanism underlying
the cytotoxic effect of S109, we evaluated the nuclear
localization of different tumor-suppressor proteins
through western blot analysis and fluorescence micros-
copy. As presented in Fig. 4a, the exposure of U87 cells
to S109 resulted in an increased nuclear accumulation of
key tumor-suppressor proteins (Foxo1, p21, and p27)
compared with the control. Foxo1 was detected exclu-
sively in the cytoplasm in untreated cells, as determined
by immunofluorescence (Fig. 4d, e). However, S109
treatment induced the nuclear accumulation of Foxo1 as
early as 2 h post-treatment in both U87 and U251 cells.
In addition, S109 also significantly enhanced the accu-
mulation of p53 and p21 in the nucleus in both cell lines
(Fig. 4f–i). The nuclear retention of these tumor-
suppressor proteins is implicated in the triggering of
cell-cycle arrest. These findings are consistent with the
results of our cell-cycle analysis, suggesting that tumor-
suppressor proteins play a role in CRM1-mediated cell-
cycle arrest.
In glioma cells, Foxo1 and Rb1 can be inactivated by
hyperphosphorylation [33, 34], and phosphorylated
Foxo1 is exported from the nucleus in a CRM1-
dependent manner. Therefore, we analyzed the effects of
S109 on the phosphorylation of Foxo1 and Rb1 in gli-
oma cells. A western blot analysis revealed a decrease in
the level of the phosphorylated form of Foxo1 in glioma
cells compared with the control cells (Fig. 4b). Similarly,
S109 significantly decreased the level of phosphorylated
Rb1 in a dose-dependent manner. However, no signifi-
cant change in the levels of Akt phosphorylation was ob-
served. Taken together, these data indicate that S109
might simultaneously perturb mediators of the critical
pathways associated with glioma (the Foxo1, p53, and
Rb1 signaling pathways) by promoting the nuclear reten-
tion of key tumor-suppressor proteins.
To determine whether S109 directly disrupts the inter-
action between CRM1 and cargo proteins, we incubated
U87 cells in media with or without S109 and analyzed
the protein extracts through immunoprecipitation as-
says. As shown in Fig. 4c, the tumor-suppressor proteins
Foxo1, p27, and p53 were capable of binding CRM1 in
the untreated cells. However, only low levels of these
proteins co-precipitated with CRM1 in the treated sam-
ples, indicating that S109 treatment significantly inhib-
ited the interaction of these proteins with CRM1. These
results suggest that S109 might directly disrupt the
interaction of CRM1 with the tumor-suppressor proteins
Foxo1, p27, and p53.
The CRM1 Cys528 mutation abrogates S109 activity in
glioma cells
The Cys528 residue in the cargo-binding pocket of
CRM1 is essential for the inhibitory effect of LMB [35].
Thus, we investigated the effects of the Cys528 mutation
in CRM1 on S109 activity in glioma cells. We developed
two U87 cell lines stably expressing either exogenous
wild-type CRM1 or CRM1 with the Cys528 mutation.
As shown in Fig. 5a, S109 induced CRM1 degradation in
the cells expressing wild-type CRM1 but not in the cells
expressing mutant CRM1. Furthermore, we did not ob-
serve RanBP1 nuclear accumulation in the cells express-
ing the CRM1 Cys528 mutant protein after S109
treatment (Fig. 5b).
We then explored the anti-tumor activity of S109 in
U87 cells expressing mutant CRM1. Consistent with our
previous observation, S109 treatment significantly inhib-
ited the growth of the cells expressing wild-type CRM1
(Fig. 5c–e). However, the inhibitory effects of S109 on
the growth of glioma cells were nearly abolished in the
cells expressing Cys528 mutant CRM1. We also evalu-
ated the effect of mutant CRM1 on the regulation of the
cell cycle by S109. As shown in Fig. 5f, S109 treatment
resulted in cell-cycle arrest at the G1 phase in the cells
expressing wild-type CRM1. Notably, no marked
changes in cell-cycle progression were observed after
S109 treatment in the cells expressing mutant CRM1.
Our data demonstrate that S109 can selectively bind the
Cys528 residue of CRM1 with few off-target effects at
the concentration used in these experiments.
S109 treatment is effective and safe in an intracranial
glioblastoma xenograft model
To determine whether S109 exerts anti-tumor activity
on glioblastoma cells in vivo, we evaluated its effect in
an intracranial nude mouse model. S109 treatment was
initiated at the first sign of tumor growth, as indicated
through an imaging analysis. Treatment with S109 sig-
nificantly suppressed the growth of U87 glioblastoma
cells in vivo, as indicated by a marked increase in the
bioluminescence signal observed in mice treated with
the vehicle control compared with the S109-treated mice
(Fig. 6a, b). In addition, 21 days after glioma transplant-
ation, the transplanted gliomas in S109-treated mice
were visibly smaller than those in the vehicle-treated
mice (Fig. 6c). Consequently, the S109-treated mice
Liu et al. Journal of Hematology & Oncology  (2016) 9:108 Page 8 of 14
Fig. 4 S109 perturbs the core pathways associated with glioma by promoting the nuclear retention of tumor-suppressor proteins. a U87 cells
were treated with vehicle or S109 (2 μM) for 12 h. The cytoplasmic and nuclear protein extracts were analyzed by immunoblotting with the indi-
cated antibodies. b U87 and U251 cells were cultured in the absence or presence of S109 for 24 h. Cell lysates were then prepared and analyzed
by immunoblotting. c S109 disrupts the interaction of CRM1 with tumor-suppressor proteins. U87 cells were treated with S109 (2 μM) for 2 h. Cell
lysates were immunoprecipitated using CRM1 antibody and evaluated by western blotting. d–i The cells were treated with vehicle, LMB (2 nM) or
S109 at the indicated concentrations for 12 h. The localization of Foxo1, p21, and p53 was analyzed by fluorescence microscopy
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exhibited significantly increased survival (Fig. 6d). Fur-
thermore, our data demonstrated that S109 could effect-
ively cross the blood-brain barrier (Additional file 1:
Figure S4).
To examine the effect of S109 on CRM1 expression in
vivo, we immunostained tumor tissues isolated from
S109-treated mice. As expected, CRM1 protein expres-
sion was markedly decreased in the S109-treated tumor
cells compared with the control tumor cells (Fig. 6e). In
addition, we evaluated the proportion of Ki67-positive
cells because this parameter is often used to evaluate
tumor cell proliferation and histology. As shown in
Fig. 6f, the proportion of Ki67-positive tumor cells in the
mice treated with S109 was significantly lower than that
found in the mice treated with vehicle. In addition, we
evaluated the histology of cells from the liver, heart,
testis, lungs, and kidneys of the vehicle- and S109-
treated mice. The specimens were formalin-fixed and
Fig. 5 Mutation of CRM1 abolishes the anti-proliferative activity of S109 in glioma cells. a U87 cells expressing wild-type or C528S-mutant CRM1
were treated with the indicated doses of S109 for 12 h and evaluated by western blot analyses. b U87 cells expressing wild-type or C528S-
mutant CRM1 were cultured in media with vehicle or S109 (2 μM) for 2 h. Fixed cells were stained for RanBP1 and DAPI and analyzed by fluores-
cence microscopy. c The cells were treated with vehicle or different concentrations of S109 for 72 h, and the cell viability was assessed through
CCK-8 assays. d Quantitative analysis of the relative cell proliferation rate. The cell proliferation rate was measured using the EdU incorporation
assay. e Assay of the colony formation ability of cells expressing wild-type or C528S-mutant CRM1. f Cell cycle distribution of U87 cells expressing
wild-type or C528S-mutant CRM1 treated with S109 for 12 h
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stained with hematoxylin/eosin, and no significant
pathological changes were observed in the organs exam-
ined (Fig. 6g). These data indicate that S109 effectively
targets intracranial gliomas without exerting any appar-
ent toxicity to normal tissues.
Discussion
Effective chemotherapies for gliomas are limited, and
improving long-term survival in glioma patients is im-
perative [36]. Therefore, new modalities that can im-
prove or replace the current treatments for gliomas are
highly desirable. This study demonstrates that S109 ex-
erts anti-tumor effects in glioma models in vitro and in
vivo. Furthermore, we discovered that S109 exerts its
anti-tumor effects by perturbing the three core pathways
implicated in glioma: the RTK/AKT/Foxos signaling
pathway and the p53 and Rb1 tumor-suppressor
pathways.
CRM1 overexpression in human gliomas is associated
with a poor prognosis and higher grade of malignancy
[18]. Therefore, targeting CRM1 is a promising thera-
peutic strategy for gliomas. Our data support this hy-
pothesis because we found that the CRM1 inhibitor
S109 significantly suppresses the proliferation of glioma
cells both in vitro and in vivo. The irreversible inhibitor
of CRM1, KPT-330, also exerts anti-tumor activity in
preclinical models of glioblastoma [37], but the molecu-
lar mechanism and cellular signaling pathways mediating
the anti-glioma activity of KPT-330 remain unknown.
The anti-glioblastoma effects of KPT-330 treatment re-
sult from the induction of apoptosis but are not associ-
ated with cell-cycle arrest [37]. In contrast, the anti-
proliferative activity of S109 results from the induction
of cell-cycle arrest in the G1 phase but does not appear
to be associated with apoptosis. This discrepancy be-
tween the mechanism of KPT-330 and that of S109
might be related to the reversible binding of S109 to
CRM1 or to a greater selectivity for CRM1. CRM1 can
recognize and transport the leucine-rich nuclear export
signal (NES) of cargo proteins, including transcription
factors and tumor suppressor proteins such as p53, p21,
p27, and Foxos. The inhibition of CRM1 function could
disrupt and retain tumor suppressor proteins in the nu-
cleus to induce cancer cell cycle arrest or apoptosis.
A number of genetic alterations have been implicated
in processes that promote glioma progression, such as
increased proliferation, resistance to apoptosis, and ro-
bust invasive capability [38]. The EGFR pathway has
generated particular interest as a drug target. However,
EGFR kinase inhibitors have demonstrated disappointing
results in patients with gliomas [39]. The resistance of
gliomas to this treatment approach might be due to the
role of oncogenic mutations in genes that function up-
and mid-stream of the EGFR/Akt pathway. This hypoth-
esis raises the possibility that molecules that function
upstream of the EGFR/Akt pathway might not be opti-
mal therapy targets. Foxo transcription factors, the crit-
ical downstream transcription factors of the EGFR/Akt
pathway, are inactivated by cytoplasmic mislocalization
in glioma cells [40, 41]. High cytoplasmic Foxo1 expres-
sion in human gliomas is associated with a higher grade
of malignancy [42]. However, it is difficult to develop
direct inhibitors of transcription factors. In this manu-
script, we report that the inhibition of CRM1 by S109
might significantly promote the nuclear retention of
Foxo1, and our results indicate that redirecting Foxo1 to
the nucleus by inhibiting CRM1 might be an effective
approach for treating gliomas.
Inactivation of the p53 and Rb1 tumor-suppressor
pathways is frequently observed in glioma cells. The pro-
teins p14/ARF and p16/INK4A are the key regulators of
the p53 and Rb1 signaling pathways, respectively [43]. In
human gliomas, one of the most common genetic aber-
rations is the homozygous deletion of CDKN2A. Because
CDKN2A encodes both p14/ARF and p16/INK4A, the
deletion of CDKN2A results in the disruption of both
the p53 and Rb1 pathways [4]. We found that S109
treatment induces the nuclear accumulation of p53 and
decreases the level of Rb1 phosphorylation. Rb1 is a
well-characterized protein that functions as a key nega-
tive regulatory protein of cell-cycle progression from the
G1 phase. Thus, one of the mechanisms through which
S109 induces G1 cell-cycle arrest is by promoting the
nuclear retention of Rb1. Interestingly, we observed that
high-grade glioma cells are more sensitive to S109 treat-
ment than low-grade cells. This difference might be re-
lated to the observation that the three core oncogenic
pathways are more frequently disrupted in high-grade
glioma cells [4]. Taken together, our results indicate that
(See figure on previous page.)
Fig. 6 Effects of S109 in vivo. a S109 inhibits glioma cell growth in vivo. Animals with U87 xenografts were separated into the control and
treatment groups once luciferase-expressing tumors were confirmed by a bioluminescence imaging system. Representative pseudocolor bio-
luminescence images obtained on days 7, 14, and 21 are shown. b Quantified luminescence signal obtained from the mice-bearing luciferase-
labeled gliomas treated with S109. c Representative images of H&E staining of coronal sections from mouse brains with orthotopic tumors. d The
survival of mice with tumors derived from the vehicle or S109-treated groups was measured by Kaplan-Meier survival curves. e, f Representative
images of CRM1 and Ki-67 immunostaining of tumors dissected from control and S109-treated mice. g H&E-stained tissue sections of the lungs,
livers, testes, kidneys, and hearts from the control and S109-treated mice were examined. Scale bar, 100 μm
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S109 treatment can simultaneously target the three core
pathways implicated in glioma. Therefore, the targeted
inhibition of CRM1 is an attractive strategy for the treat-
ment of gliomas.
Conclusions
In summary, our results affirm that S109 is an effective
reversible inhibitor of CRM1 and that CRM1 is an at-
tractive molecular target for the development of molecu-
lar therapeutics for glioma. In particular, we have
provided strong evidence that the underlying mechanism
of action of S109 involves a perturbation of the three
core pathways in human glioma cells that is mediated by
the nuclear retention of tumor-suppressor proteins.
These findings highlight the potential of future clinical
trials evaluating the therapeutic potential of S109 for the
treatment of human gliomas.
Additional file
Additional file 1: Figure S1 Knockdown of CRM1 inhibits the
proliferation of glioma cells. (A) Expression of CRM1 was analyzed from
273 samples of different glioma types based on R2 genomics database.
(B) U87 cells were infected with either a CRM1-specific shRNA or control
shRNA. CRM1 knockdown was evaluated by immunoblotting. (C) The
proliferation of U87 cells was measured by CCK-8 assay. Figure S2. S109
suppresses glioma cell proliferation in a time-independent manner. (A
and B) U87 and U251 cells were treated with S109 at the indicated doses
for different periods of time. Cell proliferation was assessed using the
EdU incorporation assay. Figure S3. S109 reversibly inhibits the function
of CRM1. (A and C) U87 and U251 cells were incubated with S109 or LMB
for 2 h. Fixed cells were stained for RanBP1 and DAPI and analyzed by
fluorescence microscopy. (B and D) U87 and U251 cells were treated with
S109 or LMB for 2 h. Next, the inhibitors were washed out and fresh
medium was added. The cells were further incubated for 2 h, stained
with anti-RanBP1 and DAPI, and analyzed by fluorescence microscopy.
Figure S4. The pharmacokinetic characteristics of S109 in plasma and
cerebrospinal fluid (CSF). S109 (50 mg/Kg) was administered to rats via
intraperitoneal injections. Blood and cerebrospinal fluid samples were
collected at 10, 20, and 30 min post-dose. The concentrations of S109 in
plasma and cerebrospinal fluid were determined by LC-MS/MS,
respectively. (DOCX 5829 kb)
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